Dosimetry and Immunohistochemistry Study to Establish Radiolabelled PSMA as a Potential Target in Glioma Treatment

Trial ID: NCT05263466

Interventional - Phase Unknown - Not yet recruiting

A study is being performed to observe whether a novel type of brain imaging using a technique called PET-MRI may provide useful information in the 'mapping' of adult primary brain tumours. It employs a radiolabelled molecule targeting a particular molecule called PSMA which is hypothesised to be a marker of aggression in primary brain tumours. 'Mapping' of the concentration and distribution of this molecule within brain tumours via PET-MRI may provide vital clinical information regarding the extent and timing of treatment.

Conditions

• Glioma, Malignant

Interventions

• PET-MRI
• Brain tumour biopsy

Eligibility

Inclusion criteria

• - Individuals of 18 years or older
• Referred for surgery (resection or biopsy) of presumed high grade primary brain tumour (based on imaging features of aggression e.g. perfusion imaging, diffusion restriction etc.). As standard, all patients will have had a full body CT and other investigations to rule out metastatic disease (this has a very high negative predictive value).
• Written informed consent

Exclusion criteria

• - Patient already enrolled in a drug trial
• Contra-indication for MRI contrast
• Contra-indication for radiotracer
• Inability to give consent
• Patient is pregnant or planning to become pregnant

Sponsor

King's College Hospital NHS Trust

Source: Clinicaltrials.gov

Search more clinical trials on myTomorrows